Plus, another Hormuz plan.
First quarter earnings season is in full swing, with a full slate of semiconductor and consumer companies slated to report ...
Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results